- Transcenta to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer
- Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
- Transcenta Presented Two Scientific Posters at SITC 2022 Annual Meeting
- Transcenta to Hold 3 Exchange Sessions on Post-SITC Business Update Call & TST003 data release and pipeline development progress update
Transcenta Holding Limited (6628:HKG) closed at 3.03, 42.92% above the 52 week low of 2.12 set on Aug 24, 2022.
2.12Aug 24 20228.15Jan 28 2022
|Market cap||1.27bn HKD|
|EPS (TTM)||-2.41 |
Data delayed at least 15 minutes, as of Jan 27 2023 08:08 GMT.